Emerging therapies in castrate-resistant prostate cancer

Luai Zarour, Joshi Alumkal

    Research output: Contribution to journalArticle

    11 Citations (Scopus)

    Abstract

    Prostate cancer is the most common cancer in men in the United States, and despite screening and early treatment, more than 27,000 men are predicted to die of the disease this year, almost all of whom will die of castrate-resistant, metastatic cancers that have progressed despite androgen deprivation therapy, also known as hormonal therapy. In recent years, an increased understanding of molecular mechanisms of prostate cancer progression and castration resistance has led to improved treatment strategies. This review focuses on emerging therapies for the treatment of castrate-resistant prostate cancer, with an emphasis on the importance of the drug targets as well as the state of current clinical trials, including those utilizing hormonal therapies, biological agents, and immunotherapy that are underway or have recently been completed.

    Original languageEnglish (US)
    Pages (from-to)152-158
    Number of pages7
    JournalCurrent Urology Reports
    Volume11
    Issue number3
    DOIs
    StatePublished - 2010

    Fingerprint

    Prostatic Neoplasms
    Therapeutics
    Castration
    Biological Factors
    Immunotherapy
    Androgens
    Neoplasms
    Clinical Trials
    Pharmaceutical Preparations

    Keywords

    • Castration-resistant
    • Prostate cancer

    ASJC Scopus subject areas

    • Urology
    • Medicine(all)

    Cite this

    Emerging therapies in castrate-resistant prostate cancer. / Zarour, Luai; Alumkal, Joshi.

    In: Current Urology Reports, Vol. 11, No. 3, 2010, p. 152-158.

    Research output: Contribution to journalArticle

    @article{7df14a9242d7446699bdb118615bd7b3,
    title = "Emerging therapies in castrate-resistant prostate cancer",
    abstract = "Prostate cancer is the most common cancer in men in the United States, and despite screening and early treatment, more than 27,000 men are predicted to die of the disease this year, almost all of whom will die of castrate-resistant, metastatic cancers that have progressed despite androgen deprivation therapy, also known as hormonal therapy. In recent years, an increased understanding of molecular mechanisms of prostate cancer progression and castration resistance has led to improved treatment strategies. This review focuses on emerging therapies for the treatment of castrate-resistant prostate cancer, with an emphasis on the importance of the drug targets as well as the state of current clinical trials, including those utilizing hormonal therapies, biological agents, and immunotherapy that are underway or have recently been completed.",
    keywords = "Castration-resistant, Prostate cancer",
    author = "Luai Zarour and Joshi Alumkal",
    year = "2010",
    doi = "10.1007/s11934-010-0104-x",
    language = "English (US)",
    volume = "11",
    pages = "152--158",
    journal = "Current Urology Reports",
    issn = "1527-2737",
    publisher = "Current Science, Inc.",
    number = "3",

    }

    TY - JOUR

    T1 - Emerging therapies in castrate-resistant prostate cancer

    AU - Zarour, Luai

    AU - Alumkal, Joshi

    PY - 2010

    Y1 - 2010

    N2 - Prostate cancer is the most common cancer in men in the United States, and despite screening and early treatment, more than 27,000 men are predicted to die of the disease this year, almost all of whom will die of castrate-resistant, metastatic cancers that have progressed despite androgen deprivation therapy, also known as hormonal therapy. In recent years, an increased understanding of molecular mechanisms of prostate cancer progression and castration resistance has led to improved treatment strategies. This review focuses on emerging therapies for the treatment of castrate-resistant prostate cancer, with an emphasis on the importance of the drug targets as well as the state of current clinical trials, including those utilizing hormonal therapies, biological agents, and immunotherapy that are underway or have recently been completed.

    AB - Prostate cancer is the most common cancer in men in the United States, and despite screening and early treatment, more than 27,000 men are predicted to die of the disease this year, almost all of whom will die of castrate-resistant, metastatic cancers that have progressed despite androgen deprivation therapy, also known as hormonal therapy. In recent years, an increased understanding of molecular mechanisms of prostate cancer progression and castration resistance has led to improved treatment strategies. This review focuses on emerging therapies for the treatment of castrate-resistant prostate cancer, with an emphasis on the importance of the drug targets as well as the state of current clinical trials, including those utilizing hormonal therapies, biological agents, and immunotherapy that are underway or have recently been completed.

    KW - Castration-resistant

    KW - Prostate cancer

    UR - http://www.scopus.com/inward/record.url?scp=77952233948&partnerID=8YFLogxK

    UR - http://www.scopus.com/inward/citedby.url?scp=77952233948&partnerID=8YFLogxK

    U2 - 10.1007/s11934-010-0104-x

    DO - 10.1007/s11934-010-0104-x

    M3 - Article

    C2 - 20425621

    AN - SCOPUS:77952233948

    VL - 11

    SP - 152

    EP - 158

    JO - Current Urology Reports

    JF - Current Urology Reports

    SN - 1527-2737

    IS - 3

    ER -